CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 77 filers reported holding CYTOSORBENTS CORP in Q2 2018. The put-call ratio across all filers is 0.71 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $56,000 | -37.1% | 17,653 | -17.2% | 0.00% | – |
| Q4 2021 | $89,000 | -53.6% | 21,321 | -9.8% | 0.00% | – |
| Q3 2021 | $192,000 | -55.2% | 23,625 | -58.5% | 0.00% | -100.0% |
| Q2 2021 | $429,000 | -20.6% | 56,880 | -8.5% | 0.00% | 0.0% |
| Q1 2021 | $540,000 | +9.1% | 62,166 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $495,000 | -0.2% | 62,166 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $496,000 | -3.7% | 62,166 | +19.6% | 0.00% | 0.0% |
| Q2 2020 | $515,000 | +41.1% | 51,994 | +10.0% | 0.00% | 0.0% |
| Q1 2020 | $365,000 | +102.8% | 47,278 | +1.2% | 0.00% | – |
| Q4 2019 | $180,000 | -23.4% | 46,733 | 0.0% | 0.00% | – |
| Q3 2019 | $235,000 | -23.9% | 46,733 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $309,000 | -12.7% | 46,733 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $354,000 | -3.3% | 46,733 | +3.3% | 0.00% | 0.0% |
| Q4 2018 | $366,000 | -37.3% | 45,251 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $584,000 | +18.0% | 45,251 | +4.1% | 0.00% | 0.0% |
| Q2 2018 | $495,000 | – | 43,452 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $1,616 | 1.58% |
| Skylands Capital, LLC | 2,793,470 | $10,028,557 | 1.44% |
| Sargent Investment Group, LLC | 1,289,546 | $4,629,470 | 1.12% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 237,940 | $854,205 | 0.96% |
| Avenir Corp | 2,719,732 | $9,763,838 | 0.86% |
| Granahan Investment Management | 1,616,587 | $5,803,547 | 0.18% |
| Seelaus Asset Management LLC | 20,450 | $73 | 0.06% |
| Cowen Prime Advisors LLC | 42,301 | $151,861 | 0.05% |
| HighMark Wealth Management LLC | 10,000 | $35,900 | 0.03% |
| Key Client Fiduciary Advisors, LLC | 12,000 | $43,080 | 0.02% |